ArticleJournal of magnetic resonance imaging : JMRI2026
An Expanded T2-FLAIR Mismatch Phenotype in IDH-Mutant Astrocytomas.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "An Expanded T2-FLAIR Mismatch Phenotype in IDH-Mutant Astrocytomas".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe T2-FLAIR mismatch (T2FM) sign is a highly specific imaging biomarker for isocitrate dehydrogenase (IDH)-mutant astrocytomas; however, its strict definition limits clinical applicability. PURPOSE: To determine whether an expanded T2FM (eT2FM) phenotype could improve identification of IDH-mutant astrocytomas and capture prognostic and biological information. STUDY TYPE: Retrospective. POPULATION: 349 patients (50.14% male; mean age, 41.08 ± 10.40 years) with IDH-mutant astrocytomas. FIELD STRENGTH/SEQUENCE: 3 T, T1-weighted gradient-echo- or spin-echo-based images, and T2-weighted, T2 fluid-attenuated inversion recovery (FLAIR), and contrast-enhanced T1-weighted images mainly acquired using spin-echo-based techniques. ASSESSMENT: The eT2FM phenotype was defined by incorporating spatially heterogeneous T2 FLAIR signals beyond the classic T2FM sign. Survival differences were compared between eT2FM and non-eT2FM tumors. Survival associations were evaluated. Metabolomic profiling was explored. STATISTICAL TESTS: Kaplan-Meier analysis, weighted log-rank test, Cox regression, and metabolomic analyses. Significance was set at p < 0.05.
resultsThe eT2FM phenotype was identified in 116 of 349 patients (33.24%; mean age, 39.08 ± 9.51 years), exceeding classic T2FM (50/349, 14.33%; mean age, 36.40 ± 9.10 years). Kaplan-Meier analysis showed more favorable overall survival for eT2FM than non-eT2FM tumors, with restricted mean survival time (RMST) up to 36 months of 35.18 and 32.08 months, respectively (absolute difference, 3.10 months). Similar findings were observed in the external validation cohort, in which eT2FM phenotype was identified in 48 of 146 patients (32.88%; mean age, 37.77 ± 11.05 years). Kaplan-Meier analysis also showed more favorable overall survival for eT2FM than non-eT2FM tumors, with RMSTs of 36.00 and 33.81 months, respectively (absolute difference, 2.19 months). The eT2FM phenotype was associated with better prognosis in univariable Cox analysis (HR, 0.265; 95% CI, 0.120-0.585), but not independently in multivariable analysis (HR, 2.014; 95% CI, 0.380-10.673; p = 0.41). Exploratory metabolomics identified 1078 differentially abundant features between groups. DATA
conclusionThe eT2FM phenotype extends the clinical utility of classic T2FM sign and delineates a subgroup of IDH-mutant astrocytomas with favorable clinicopathologic features. LEVEL OF EVIDENCE: 4: TECHNICAL EFFICACY: Stage 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.